AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Delivery Of Genes To Leukemia Cells Offers Promise For Cancer Vaccine.(Brief Article)
2001 MAR 28 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - Gene transfer to leukemic cells via a lentivirus vector may one day be useful in the development of a cancer vaccine.
"We adopted a defective lentivirus derived from the human immunodeficiency virus (HIV)-1 backbone and carrying the enhanced green fluorescent protein (EGFP) gene to transduce primary human acute myelogenous leukemia (AML) and B-precursor acute lymphoblastic leukemia (ALL) cells," explained E. Biagi and colleagues at the University of Milan, Italy.
Cell proliferation was apparently unnecessary, but cell wall viability critical, to the infection rate of AML cells, noted the researchers. After seven days, the infection rate varied from 8.4% to 37%.
In the ALL precursor cells, the infection rate varied from 4.4%-21% after three days, reported Biagi et al. ("Efficient lentiviral transduction of primary human acute myelogenous and lymphoblastic leukemia cells," Haematologica, 2001;86(1):13-16).
"These preliminary data suggest that gene delivery into primary human AML and B-precursor ALL cells by an HIV-1 ...
- NY-ESO-1 shows promise as antigen for breast cancer vaccine development.
- Newspaper article from: Vaccine Weekly May 12, 2004 700+ words
...subject areas of Breast Cancer Vaccine, Breast Cancer Therapy, Cancer Vaccine, Vaccine Development...article was prepared by Vaccine Weekly editors from staff and...reports. Copyright 2004, Vaccine Weekly via NewsRx.com &...
- Cancer vaccine delivers antigen to dendritic cells.
- Newspaper article from: Vaccine Weekly February 11, 2004 700+ words
...adenoviral vector cancer vaccine that delivers a tumor...adenoviral vector cancer vaccine that delivers a tumor...major subject areas of Cancer Vaccine, Immunology, Immunotherapy...article was prepared by Vaccine Weekly editors from staff...
- New cancer vaccine program launched.
- Newspaper article from: Vaccine Weekly February 11, 2004 700+ words
...joined forces to develop a therapeutic cancer vaccine program at a state-of-the-art cancer vaccine laboratory opened earlier this year...for vaccine production. The global cancer vaccine program, anchored in Ontario, has...
- Scientists discover SSX, a new family of cancer vaccine targets.
- Newspaper article from: Vaccine Weekly April 28, 2004 700+ words
...Scientists from the Cancer Vaccine Collaborative (CVC) have...particularly good target for a cancer vaccine," said Dr. Danila Valmori...We believe that for a cancer vaccine to be effective, you really...article was prepared by Vaccine Weekly editors from staff and ...
- Prostate cancer vaccine on track for phase III clinical trials.
- Newspaper article from: Vaccine Weekly November 27, 2002 700+ words
...development activities in both its GVAX cancer vaccine and oncolytic virus therapy programs...including our lead program, GVAX prostate cancer vaccine, which is on track to enter phase...multicenter phase II trial of GVAX prostate cancer vaccine in patients with hormone refractory...
- Breast cancer vaccine trial completed.(Brief Article)
- Newspaper article from: Vaccine Weekly January 15, 2003 700+ words
...from a phase I/II breast cancer vaccine clinical trial. The findings...the development of this cancer vaccine approach was performed at...supports our broad approach in cancer vaccine development," stated Gail...article was prepared by Vaccine Weekly editors from staff ...
- Biopharma signs agreement to manufacture Coley's Toxin cancer vaccine.
- Newspaper article from: Vaccine Weekly July 28, 2004 700+ words
...produce Coley's Toxin cancer vaccine for clinical trials...challenging microbial cancer vaccine, and as an academic...article was prepared by Vaccine Weekly editors from staff...Copyright 2004, Vaccine Weekly via NewsRx.com...
- Cancer vaccine maker posts net loss of $0.43 per share.
- Newspaper article from: Vaccine Weekly February 25, 2004 700+ words
...product candidate, GVAX prostate cancer vaccine, which is targeted to enter phase...This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2004, Vaccine Weekly via NewsRx.com & NewsRx...
- IMC-BEC2 cancer vaccine trial did not meet primary endpoint.
- Newspaper article from: Vaccine Weekly July 7, 2004 700+ words
...trial of the companies' IMC-BEC2 cancer vaccine did not meet its primary endpoint...This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2004, Vaccine Weekly via NewsRx.com & NewsRx...
- Commercial agreement announced for cancer vaccine product candidate.
- Newspaper article from: Vaccine Weekly April 7, 2004 700+ words
...of CancerVac's most advanced cancer vaccine product candidate. Biomira will...This article was prepared by Vaccine Weekly editors from staff and other reports. Copyright 2004, Vaccine Weekly via NewsRx.com & NewsRx...
Source: HighBeam Research, Delivery Of Genes To Leukemia Cells Offers Promise For Cancer...